COMMUNIQUÉS West-GlobeNewswire

CROSSJECT : Bilan de fin de contrat de liquidité

13/09/2017 - 18:32

Bilan de fin de contrat de liquidité conclu avec CM-CIC Market Solutions Dijon, le 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments [...]

CROSSJECT : Descriptif du programme de rachat d'actions

13/09/2017 - 18:28

Descriptif du programme de rachat d'actions 2017-2018 Dijon, le 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments combinés innovants [...]

CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social

13/09/2017 - 18:20

Information relative au nombre total de droits de vote et d'actions composant le capital social 13 septembre 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de [...]

Xultophy® reduces cardiovascular risk factors in people with type 2 diabetes

13/09/2017 - 16:32

Lisbon, Portugal, 13 September 2017 - In people with type 2 diabetes, Xultophy ® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease [...]

CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

13/09/2017 - 16:27

SANTA CLARA, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]

Solon Eiendom ASA : Finansiell kalender

13/09/2017 - 16:19

(Oslo, Norge, 13 september 2017) Solon Eiendom ASA har gjort følgende endringer i finansiell kalender for 2017: 9 November 2017 Kvartalsrapport Q3 Presentasjonen er fremskyndet for å gi mest mulig tidsriktig informasjon [...]

Solon Eiendom ASA : Financial calender

13/09/2017 - 16:18

(Oslo, Norway, 13 September 2017) Solon Eiendom ASA has rescheduled its financial calendar 2017 as follows: 9 November 2017 Q3 2017 Interim Financial Report In order to present information more timely we have decided to [...]

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease

13/09/2017 - 13:30

TORONTO and CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced it has [...]

RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

13/09/2017 - 13:00

Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and [...]

NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373

13/09/2017 - 13:00

Received Best Poster Presentation Award at ESMO 2017 EDINBURGH, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- NuCana plc announced the presentation of interim first-in-human data from a Phase 1 clinical study of [...]

Soliqua® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL

13/09/2017 - 12:17

Press release - No. 7/2017 Soliqua ® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL More adults reached HbA 1c target at 8 and 12 weeks versus those receiving insulin glargine 100 units/ [...]

Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer

13/09/2017 - 11:00

Heidelberg, Germany, September 13, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the [...]

Nicox : Rapport semestriel financier au 30 juin 2017

13/09/2017 - 10:55

Communiqué de presse Nicox : Rapport semestriel financier au 30 juin 2017 13 septembre 2017 Sophia Antipolis, France Le Rapport Semestriel Financier et d'Activité de la société Nicox S.A. au 30 juin 2017 visé à l' [...]

Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data

13/09/2017 - 07:15

Cosentyx ® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI 90 and PASI 100 response rates were [...]

Biocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

13/09/2017 - 07:00

PRESS RELEASE: REGULATED - INSIDE INFORMATION Wednesday September 13, 2017, 07:00 CEST Tuesday September 12, 2017, 22:00 PT Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX ® [...]

Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials

12/09/2017 - 20:00

Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD DUBLIN and LAS VEGAS - September 12, 2017 - Medtronic plc (NYSE: MDT) data announced today reinforce the durability [...]

Deinove : Le projet « AGIR » obtient une aide de 14,6 millions d'euros du PIA

12/09/2017 - 18:00

Communiqué de presse 12 SEPTEMBRE 2017 Le projet « AGIR » porté par le groupe DEINOVE bénéficie d'une aide de 14,6 millions d'euros du Programme d'Investissements d'Avenir (PIA) opéré par Bpifrance pour développer de [...]

Deinove : The AGIR project carried out by the DEINOVE group is granted €14.6 m

12/09/2017 - 18:00

Press release 12 September 2017 The AGIR project carried out by the DEINOVE group is granted €14.6 million by the 'Investments for the Future' Program (IFP) operated by Bpifrance to develop new antibiotics. The AGIR [...]

Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

12/09/2017 - 15:48

Oslo, Norway, 12 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start of patient [...]